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Summary: This paper describes a fully mechanized homogeneous immunoassay using the immunoactivation
method for the rapid and specific determination of human granulocyte elastase (EC 3.4.21.37) in plasma. The
method uses anti-elastase antibody Fragments from sheep, conjugated to horseradish peroxidase. These enzyme-
antibody conjugates bind to the elastase-arproteinase inhibitor complex present in plasma. A separate sample
blank with non-specific sheep antibody fragments conjugated to horseradish peroxidase corrects for errors
introduced by the sample matrix. Measurements were performed with the clinical chemistry analyser Hitachi®
717. A single determination can be performed in 10 min, requiring 24 μΐ sample volume. The measuring r nge
is about 20 to 1000 μg/l elastase. For within-run precision the coefficients of Variation are 4.77%, 4.48% and
1.85% for elastase concentrations of 45.7, 89.1 and 385.4 μg/l; for day-to-day precision the coefficients of
Variation are 15.81%, 7.19% and 4.12% for elastase concentrations of 31.1, 65.5 and 440.2 μ§/1, respectively.
Correlation (y = bx + a) of results with those from the heterogeneous immunoassay showed a good agreement
(r = 0.93, b = 1.11, a == —27.0, N = 121). Interferencesby endogeneous substances and by drugs at therapeutic
doses were not observed. The reference interval, determined by using plasma from 215 healthy individuals
(C-reactive protein < 5 itig/1, leukocyte count 4—8 χ 109/1), was 9 — 56 μg/l (2.5th to 97.5th percentile), with
a median of 27 jig/1.
Introduction t · ·* r * * u * · i ^ uplasma m its free state, but is complexed by potent
Severe inj ries or infections are accompanied by a inhibitors. About 90% of all circulating elastase is
number of inflamm t ry reactions, the so-called in- present s a stable l: l complex with ocrproteinase
flammatory response. Among these reactions are the inhibitor (13, 14). This complex can be determined in
activation of humoral Systems and the Stimulation of plasma samples using a homogeneous enzyme im-
inflammatory celjs such s the polymorphon clear munoassay. The test principle of the homogeneous
granulocytes, which are well-equipped with proteo- assay, the immunoactivation method, exploits the fact
lytic enzymes, like elastase1) (l — 3). Thus, the increase that, in the presence of high concentrations of hydro-
in elastase in the plasma at an early stage reflects the gen peroxide, the enzymatic activity of polymeric
intensity of the inflaminatory Stimulus (4). As a result forms of horseradish peroxidase, after binding to the
of the rapid but graduated reaction of the granulo- elastase/arproteinase inhibitor complex, is greater
cytes, the lysosomal elastase represents a key param- than that of the monomeric forms (15 — 18). Any
eter in the diagnosis of traumatic and inflaminatory interference by the sample matrix is compensated by
processes (5 — 12). Elastase is not detectable in the a separate sample blank. This homogeneous assay
therefore makes possible the determination of elastase
κ r, D t u ι ι ™* ^locfoc^ t?r on clinical chemistry analysers. The evaluation of the') Enzyme: Polynaorphonuclear granulocyte elastase, EC ·* J .
3.4.21.37 test on Λβ Hitachi® 717 selective analyser is reported.
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Materials and Methods
Elastase was delennined wilh the PMN Elastase IMAC (im-
munoactivation) immunoassay (E. Merck, Darmstadt, Ger-
many). The kit contains antibody conjugate, blank conjugate,
Substrate B (l ,5 mmol/14-aminophenazone, 0.1 mol/1 phosphate
buffer, pH = 7.0), Substrate A (80 mmol/1 hydrogen peroxide,
50 mmol/1 phenol), and diluent for Substrate A (20 mmoi/1
TR1S buffer, pH = 7.5). The antibody conjugate consists of
sheep antibody fragmenls (Fab') against human elastase co-
valently bound to horseradish peroxidase, whereas the blank
conjugate consists of non-specific sheep antibody fragments
(Fab') covalently bound to horseradish peroxidase. For use on
the Hitachi* 717 selective analyser (Boehringer Mannheim,
Mannheim, Germany) one bottle each of lyophilized antibody
conjugate and of blank conjugate are dissolved in 10ml sub-
strate B, forming the first reagent to be pipetted (Reagent 1).
Substrate A is diluted l: 2 with the diluent for Substrate A,
forming the Start reagent (Reagent 2). Table l shows the essen-
tial parameters for the determination on the Hitachi® 717. For
the purpose of test Interpretation, 2 channels are used, i.e. one
for the sample and one for the sample blank. After calibration
of the sample channel with the commercially available calibra-
tor (E. Merck, Darmstadt, Germany), the resulting calibration
factor is read into the sample blank channel ("Calibration List"
in the "Monitor Job" menu). The Hitachi® 717 makes it possible
to calculate the interference-corrected concentration of elastase
in the sample by automatically calculating the difference be-
tween the two channels.
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The sample channel was calibrated by a linear 2-point calibra-
tion. the resulting factor was inserted into the blank channel
(modifications: Calibration Method = Factor).
A Sandwich ELISA for the determination of elastase (E. Merck,
Darmstadt, Germany) was used for method comparison. The
calibrators of this heterogeneous assay, formerly containing
only about !/3 of the given elastase content, are now based on
and recalibrated to (from batch #92019 onward) the same
highly purified Standard material also used in the PMN Elastase
IMAC immunoassay.
As sample material, sodium citrate plasma (38. g sodium citrate
per litre in the ratio l part citrate to 9 parts blood) was obtained
by venipuncture. The plasma was separated by centrifuging at
1700g for 10 min at room temperature. Samples which were
not measured immediately were stored in plastic Containers at
-70 °C. All dilution of samples was performed with the IMAC
sample dilution medium (E. Merck, Darmstadt, Germany).
C-reactive protein was determined in sodium citrate plasma on
the Behring nephelometer analyser (Behring, Marburg, Ger-
many). The reagent used was the NA Latex CRP Reagent
(Behring, Marburg, Germany). In this assay polystyrene par-
ticles coated with antibodies to C-reactive protein are agglutin-
ated by C-reactive protein in the patients' plasma. The scattered
light signal obtained on the Behring nephelometer increases in
relation to the concentration of C-reactive protein (measure-
ment r nge: 2.5—160 mg/1, reference r nge for adults: < 10
mg/1). The white blood cells were counted using K-EDTA whole
blood on the S-plus counter (Coulter, Luton, UK; reference
r nge: 4-10 χ 109/1).
Results
The test of linearity by serial dilution of a pooled
plasma showed a dependence on the concentration of
the calibrator. The lines in figure l show that after
calibration with high calibrator concentrations the
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Fig. l. Influence of the calibrator concentration on the linearity
of the elastase assay. Serial dilutions of a highly c n-
centrated plasma sample were determined in three runs
using one calibrator concentration in each ( 100 μg/l,
o 398 μg/l and Δ 960 μg/l). A regression analysis yielded
slopes of 1410 (100 μg/l), 1158 (398 μ^Ι), 1134 (960
μβ/l), and intercepts of -52.7 (100 g/l), -38.8 (398
μδ/1), -38.5 (960 fig/i). * *
The imprecision of the method was studied by deter-
mining the within-run and day-to-day precision. The
results obtained with various plasma pools are shown
in table 2. On the basis of the convincing precision
data the test can be performed s a sirigle detennU
nation.
Tab. 2. Precision of the elastase determination performed with



































Day-to-day precision was performed with a single calibration,
reflecting a calibration stability over 6 4weeks.
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The method was tested by comparing the immunoac-
tivation test on the Hitachi® analyser with the com-
mercial heterogeneous enzyme-iinked immunosorbent
assay (fig. 2). The evaluation of the results according
to a distribution-free regression analysis (19) showed
a good correlation (y = bx + a;b = 1.11, a = —27.9,
r = 0.93, N = 121). Older batches of the heteroge-
neous assay yielded concentrations 3 times higher
than those given by the IMAC assay. After conversion
of the ELISA calibrators for the highly purified raw
materials also used in the immunoactivation assay,
and recalibration of the heterogeneous assay, similar
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Fig. 2. Comparison of the horiiogeneous elastase assay on Hi-
tachi® 717 analyser vs. a commercial ELISA according
to a non-parametric regression analysis (19)
(y = bx + a; b = 1.11, a = -27.0, r = 0.93, N = 121).
Analysis of lipaemic and haemolytic samples revealed
that lipaemic samples with triacylglycerol concentra-
tions p to 5 g/l and haemolytic samples with a free
haemoglobin concentration up to l g/l in the plasma
do not influence result. The same holds for hyperbi-
lirubinaemia (plasma concentrations up to 510 μιηοΐ/l
bilkubin). However, it must be noted that there is a
lag phase in the time course of absorbance. This is
the reason why we have chosen measurement points
35 — 41 when adjusting the pafameters (fig. 3). As-
corbic acid in concentrations appreciably higher than
physiological levels (after administration of multivi-
tamin infusions) also causes noticeable interference.
A possible explanation for this is that primary oxi-
dation products of the Substrate are rapidly reduced
by the ascorbic acid (17).
Because of the high concentration of hydrogen per-
oxide used, the instrument was investigated for any
carry-over effects via the reagent pipettes and cu-
vettes. No influence on other test methods (enzyme
and Substrate determinations), observable s a devia-
tion frorn the within^ruii precision achieved by the
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Fig. 3. Reaction monitor of the Hitachi® 717 analyser with a
plasma sample containing 542 μπκ>1/1 bilirubin (* sample
channel, o blank channel). Cuvette position = meas-
urement taken every 12 seconds; Rl = addition of
antibody-conjugate, respectively blank-conjugate; R2 =
addition of Substrate A.
could be detected. Citrate plasma samples for the
determination of elastase can be frozen for months
without any loss, or stored for 24h at 4-8 °C (20).
Samples, which cannot be centrifugated immediately,
may be stored at room temperature for up to 5 h after
venipuncture; during this storage period, falsely high
values that might arise from a release reaction of the
granulocytes are not observed. Because of the separate
storage of the Substrates (4-aminophenazone in Re-
agent l, hydrogen peroxide and phenol in Reagent
2), the reagent used remains stable for weeks when
cooled in the instrument (4—8 °C). The stability of
the reagent was studied over six weeks by recording
day-to-day precision for this period. The results are
summarized in table 2.
To establish a reference r nge, citrate plasma samples
were measured from 215 healthy adults (93 women,
122 men) aged 18 to 60 years with a C-reactive protein
concentration < 10 mg/1 and a leukocyte count of
4—10 χ 109/1 (fig- 4). The median was 27 μg/l and
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Elastase (Hitachi® 717) [pg/l]
Normal values of elastase determined from 215 heaJthy
subjecls (median: 27 [ig/l> 2.5lh-97.5lh percentile: 9-56
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Discussion
The availability of suitable markers for the early di-
agnosis of complications in the course of inflamma-
tory processes facilitates more rapid and rational ther-
apeutic treatment. Due to the fact that these param-
eters are in the §/1 ränge or lower, heterogeneous
assays have been the methods of choice. However,
these techniques are rather time-consuming and not
really suitable for an emergency. The new immunoac-
tivation technique offers the advantage of a deter-
mination of elastase in the plasma in less than 15 min.
The test principle is based on the known fact that
hydrogen peroxide converts monomeric forms of hor-
seradish peroxidase via the active intermediate stages
compound I and compound II into the enzymatically
less active compound III. The oxidation states and
coordination geometrics of the different species have
been elucidated by spectrophotometric and X-ray dif-
fraction experiments (21). The native enzyme is re-
generated by the reaction of compound III with elec-
tron donors (e.Ng. phenol) via the intermediate stages
compound I and compound II. Depending on the
nature of the Substrate, high H2O2 concentrations can
lead to an accumulation of compound III and thus
to a strongly decreased enzymatic activity of mono-
meric horseradish peroxidase. In the case of polymer-
ized or aggregated horseradish peroxidase, a much
lower accumulation of compound III is observed un-
der the same conditions, so that the enzymatic activity
is appreciably higher (17, 18).
This phenomenon, which is not yet clear in detail,
forms the basis of the immunoactivation method. By
linking anti-elastase antibody fragments to horse-
radish peroxidase, monomeric conjugates are ob-
tained, which have a low enzymatic activity in the
presence of a mixture of the Substrates phenol and 4-
aminophenazone, äs well äs a high concentration of
hydrogen peroxide. If the monomeric conjugates first
react with elastase from the sample, high-molecular
immunoaggregates appear, with appreciably higher
enzyme activity. The elastase concentration in the
sample is directly proportional to the increase in en-
zymatic activity. All horseradish peroxidase effectors
and substances that exert intrinsic peroxidase activity
are potentially capable of interfering. These disturb-
ances are compensated by the use of ä special blank
conjugate, so that influence of the sample matrix can
be corrected (15, 16).
To perform the homogeneous assay on clinical chem-
istry analysers, it is necessary to occupy two channels
(sample and blank). There is a linear relationship
between the elastase concentration and the enzymatic
activity of the antibody conjugate after complexing:
this is determined by a 2-point calibration (Standard
1: §/1, Standard 2: 398 g/l). In accordance with
the nature of the blank conjugate, which is incapable
of forming immunoaggregates and thus shows no
dependence on the measurement signal from the
Standard concentration, the blank channel cannot be
calibrated in a similar way. To ijiake it possible to
base both channels on an identical linear calibration,
the factor for the sample channel obtained from the
Instrument is therefore used for the blank channel.
The reagent blank value of the blank conjugate is
then determined. Using this type of calibration en-
sures that both channels can assign the same meas-
urement Signals to the same concentration values.
Interfering influences of the sample matrix, which
cause identical modification of the measurement Sig-
nal in both channels, can now be eliminated by simply
subtracting the concentration values of one channel
from those of the other.
Free elastase does not occur in the plasma. It imme-
diately forms complexes with inhibitor, which is pres-
ent in large excess in the plasma but not in the tissues.
In addition to the elastase complexed with the a^
proteinase inhibitor in the plasma, there is a small
fraction consisting of a complex with the a2-macro-
globulin (total fraction < 10%) (13,14). This complex
does not bind with the antibody conjugate of the
homogeneous test (Dreher, M., unpublished data),
For this reason, for plasma, the specificity of the test
does not differ from that of the heterogeneous ELISA,
which has been used üp to now.
The latter is a typical sandwich immunoassay utilizing
antibodies directed against elastase and ota -proteinase
inhibitor (22). A comparison of both methods shows
a good correlation. The within-run precision and day-
to-day precision show coefficients of Variation that
are typical of tests performed on analysers. The lin-
earity over the extended measurement ränge (up to
1000 g/l) requires additional dilution only in rare
cases of massive elastase release. Apart from a few
extreme cases (e. g. high bilirubin, high ascorbic acid),
no false results have been found. No carry-over effects
of the reagent on the analyser could be detected. On
the basis of the long stability of the reagent. and the·
satisfactory stability of the sample in vitro without
special sample collection and work-up, the determi-
nation method is suitable for emergency testing.
Conclusion
The determination of elastase/a^protemase inhibitor
complex in the plasma is a sensitive, precise routine
assay, linear over a wide ränge of measurement, which
Eur. J. Clin. Chera. Clin. Biochem. / Vol. 29,1991 / No. 3
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can bc performed in less than 15 min on the Hitachi®
717 automated analyser without special treatment of
the sample.
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